Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADA | P00813 | 10/20 | 0.82 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4583534 | 0.99 | ADA (0.81) | ADAHTR3AIKBKBMAPTRXFP1 | |
| SCHEMBL4583586 | 0.93 | ADA (0.81) | ADAMAPT | |
| SCHEMBL4584344 | 0.92 | ADA (0.80) | ADAMAPTTP53 | |
| Hydrochloric Acid SCHEMBL4585536 | 0.92 | ADA (0.80) | ADAMAPT | |
| Hydrochloric Acid SCHEMBL4583903 | 0.91 | ADA (0.79) | ADAMAPTTP53 | |
| SCHEMBL4582821 | 0.91 | ADA (0.86) | ADAHTR3A | |
| SCHEMBL4583690 | 0.91 | ADA (0.86) | ADA | |
| Hydrochloric Acid SCHEMBL4582964 | 0.90 | ADA (0.84) | ADA | |
| Hydrochloric Acid SCHEMBL4583283 | 0.89 | ADA (0.98) | ADAHTR3A | |
| SCHEMBL4584354 | 0.89 | ADA (0.65) | ADAHTR3AIKBKBMAPTRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7317107-B2 | Imidazole 4-carboxamide compounds with adenosine deaminase inhibiting activity | ASTELLAS PHARMA INC. (JP) | 2008-01-08 | — | — | US | disclosed |
| US-20050159462-A1 | Imidazole 4-carboxamide compounds with adenosine deaminase inhibiting activity | ASTELLAS PHARMA INC. (JP) | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159462-A1 | Imidazole 4-carboxamide compounds with adenosine deaminase inhibiting activity | ADA, AMPD2, AMPD1 | ADA 1/4885HTR3A 747/4885IKBKB 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.